The muscle oxidative regulatory response to acute exercise is not impaired in less advanced COPD despite a decreased oxidative phenotype

PLoS One. 2014 Feb 28;9(2):e90150. doi: 10.1371/journal.pone.0090150. eCollection 2014.

Abstract

Already in an early disease stage, patients with chronic obstructive pulmonary disease (COPD) are confronted with impaired skeletal muscle function and physical performance due to a loss of oxidative type I muscle fibers and oxidative capacity (i.e. oxidative phenotype; Oxphen). Physical activity is a well-known stimulus of muscle Oxphen and crucial for its maintenance. We hypothesized that a blunted response of Oxphen genes to an acute bout of exercise could contribute to decreased Oxphen in COPD. For this, 28 patients with less advanced COPD (age 65 ± 7 yrs, FEV1 59 ± 16% predicted) and 15 age- and gender-matched healthy controls performed an incremental cycle ergometry test. The Oxphen response to exercise was determined by the measurement of gene expression levels of Oxphen markers in pre and 4h-post exercise quadriceps biopsies. Because exercise-induced hypoxia and oxidative stress may interfere with Oxphen response, oxygen saturation and oxidative stress markers were assessed as well. Regardless of oxygen desaturation and absolute exercise intensities, the Oxphen regulatory response to exercise was comparable between COPD patients and controls with no evidence of increased oxidative stress. In conclusion, the muscle Oxphen regulatory response to acute exercise is not blunted in less advanced COPD, regardless of exercise-induced hypoxia. Hence, this study provides further rationale for incorporation of exercise training as integrated part of disease management to prevent or slow down loss of muscle Oxphen and related functional impairment in COPD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / metabolism
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Case-Control Studies
  • Exercise Test
  • Exercise*
  • Female
  • Gene Expression
  • Humans
  • Hypoxia / metabolism*
  • Hypoxia / pathology
  • Male
  • Middle Aged
  • NAD / metabolism
  • Oxidative Stress
  • Oxygen Consumption
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Peroxisome Proliferator-Activated Receptors / genetics
  • Peroxisome Proliferator-Activated Receptors / metabolism
  • Pulmonary Disease, Chronic Obstructive / metabolism*
  • Pulmonary Disease, Chronic Obstructive / pathology
  • Quadriceps Muscle / metabolism*
  • RNA-Binding Proteins
  • Severity of Illness Index
  • Transcription Factors / genetics
  • Transcription Factors / metabolism

Substances

  • Biomarkers
  • Carrier Proteins
  • PPARGC1A protein, human
  • PPARGC1B protein, human
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Peroxisome Proliferator-Activated Receptors
  • RNA-Binding Proteins
  • Transcription Factors
  • NAD

Grants and funding

This study was performed within the framework of the Dutch Top Institute Pharma project T1-201. Partners within this project are Maastricht University Medical Centre+, University Medical Center Utrecht, University Medical Center Groningen, AstraZeneca, Nycomed, GlaxoSmithKline and Danone Research. All the partners approved the manuscript. Dr Gosker was funded by a Netherlands Asthma Foundation grant (NAF 3.2.09.068). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.